Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Formal study hypothesis:
Cranial reconstruction using mesenchymal stromal cells and resorbable biomaterials, will result in the patient producing their own bone to fill the void which will reduce the risk of infection and resorption, lead to a better cosmetic result and obviate any long term consequence of having a synthetic material in vivo.
Introduction:
There are several reasons that parts of the skull may need to be removed:
- After trauma to relieve brain swelling
- During brain surgery (for brain cancer)
- After trauma where the bone is so badly fractured/fragmented it needs to be removed.
In all but the last case the bone flap is temporarily stored in a freezer and once the brain swelling has subsided it is reinserted. This procedure is called "autologous cranioplasty"; autologous, because it originally came from the patient and cranioplasty, referring to the repair. Although this is a straightforward procedure, there are a number of complications including infection and bone resorption that can occur.
This study:
Stromal cells have a proven ability to aid in bony healing. Furthermore stromal cells on a ceramic framework encased in a plastic scaffold have been shown in a small clinical trial to lead to healing of skull defects. In the present study, it is proposed to add stromal cells from a suitable donor to medical grade ceramic granules, place them in between specially moulded plastic scaffolds and insert the sandwich into the skull. Both the ceramic and plastic materials are medical grade and commonly used in reconstructive surgery, the ceramic for packing into bony defects due to trauma or removal of cancer and the polymer in bony reconstruction. Both materials are approved by the TGA. They are designed to dissolve away over time as the body's own blood vessels and cells populate the sandwich and create the patient's new bone. It has been proven that without the encouragement of the cells and temporary scaffold materials, a hole in the skull will not heal. Given the incidence of bone resorption/infection and metal plate infection using traditional methods, it would seem prudent to provide a construct that will allow controlled replacement with the patient's own bone, thus negating any adverse long-term complications with synthetic materials that remain for life.
| Condition | Intervention | Phase |
|---|---|---|
|
Surgically-Created Resection Cavity |
Procedure: Repair of cranial defects by tissue engineering |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pilot Study to Demonstrate Safety and Feasibility of Cranial Reconstruction Using Mesenchymal Stromal Cells and Resorbable Biomaterials |
- Failure of cranioplasty implant [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]The primary outcome measures will be failure of the tissue engineered construct such that it requires removal (due to infection, resorption, dislodgement or cosmetic failure), as well as any significant adverse events attributable to treatment allocation.
- Quantitative bone density of the tissue engineered construct and adjacent bone from CT scan at 12 months. [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
- Assessment of cosmesis by photography [ Time Frame: 12 months ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 10 |
| Study Start Date: | January 2013 |
| Estimated Study Completion Date: | December 2015 |
| Estimated Primary Completion Date: | December 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Repair of cranial defect
Repair of cranial defects by tissue engineering
|
Procedure: Repair of cranial defects by tissue engineering
Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
|
Show Detailed Description
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- All adult patients (age > 18 years) who have had a decompressive craniectomy, with a defect size of less than 80 mm in diameter.
Exclusion Criteria:
- Patients who have had a previous cranial infection
- Patients with a penetrating bone injury
- Positive bone marrow aspirate on testing for microcontamination
- Positive testing for infectious disease
- Cranial void size of larger than 80mm
- Patients who have neurocognitive difficulties and are as such unable to provide informed consent
- Failure to sign informed consent
- Pregnant or breastfeeding females
Contacts and Locations| Contact: Stephen Honeybul, MD | 61893463333 | stephen.honeybul@health.wa.gov.au |
| Australia, Western Australia | |
| Royal Perth Hospital | Not yet recruiting |
| Perth, Western Australia, Australia, 6000 | |
| Principal Investigator: Stephen Honeybul, MD | |
| Principal Investigator: | Stephen Honeybul, MD | Royal Perth Hospital |
More Information
No publications provided
| Responsible Party: | R.P.Herrmann, Director, Cell and Tissue Therapies, Western Australia, Royal Perth Hospital |
| ClinicalTrials.gov Identifier: | NCT01742260 History of Changes |
| Other Study ID Numbers: | 2012/047, 2012/022238 |
| Study First Received: | December 3, 2012 |
| Last Updated: | December 4, 2012 |
| Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
Keywords provided by Royal Perth Hospital:
|
Cranioplasty Mesenchymal stromal cells Bioceramic polymer |
ClinicalTrials.gov processed this record on June 18, 2013